If you would rather mop your kitchen floor than get in bed with your lover this blog is for you!
It’s been six months since the Food & Drug Administration gave its blessing to the marketing of Addyi, or Flibanserin, a prescription treatment for sexual dysfunction (low libido) in premenopausal women. There seems to be a lot of controversy among medical professionals about the effectiveness of this new drug. According to a new study published in February
In August 2015, Sprout Pharmaceuticals received FDA approval for ADDYI™, known generically as Flibanserin. It is a once-daily, non-hormonal pill. The FDA had twice previously declined to approve this pill, repeatedly requesting further studies. The pill will be used for the treatment of the most common form of sexual dysfunction in premenopausal women, generalized acquired